CASI Pharmaceuticals, Inc. shares had a trading volume of 90K in the last trading session. Shares saw a steep decrease in trading volume of 94.91% under the normal average daily volume.
Traders are feeling more bearish on CASI Pharmaceuticals, Inc. of late if you put credence in the motion in short interest. The company recorded a rise in short interest of 260.18% as of October 13, 2017 from the last reporting period. Short shares grew from 113,739 to 409,668 over that period. Days to cover decreased -1.0 to 0.0 and the percentage of shorted shares is 0.01% as of October 13.
Here are a few substantial investment firms who have updated their positions. As of quarter end Citadel Advisors LLC had acquired a total of 3,626 shares growing its stake by 21.2%. The value of the total investment in CASI Pharmaceuticals, Inc. increased from $18,000 to $22,000 increasing 22.2% quarter to quarter. As of the end of the quarter Creative Planning had bought 1,478 shares growing its position 16,422.2%. The value of the investment in CASI Pharmaceuticals, Inc. went from $0 to $2,000 a change of inf% quarter over quarter.
Wellington Shields Capital Management, LLC downsized its ownership by shedding 2,378 shares a decrease of 0.3%. Wellington Shields Capital Management, LLC now controls 726,069 shares valued at $762,000. The total value of its holdings decreased 26.3%. Ubs Group Ag augmented its investment by buying 453 shares an increase of 108.1% as of 06/30/2017. Ubs Group Ag currently owns 872 shares with a value of $1,000. The value of the position overall is down by 0.0%.
The company is now up by 1.45% since yesterday’s close of $2.10. Shares of the company are trading at $2.10 which is marginally higher than the 50 day moving average of $2.04 and which is impressively higher than the 200 day moving average of $1.29. The 50 day moving average was up by +2.97% whereas the 200 day moving average was up $0.81 or +62.32%.
CASI Pharmaceuticals, Inc., launched on September 18, 1991, is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. The Company operates through the development of targeted therapeutics primarily for the treatment of cancer segment. The Business’s product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, the United States Food and Drug Administration (FDA) approved drugs in-licensed from Spectrum Pharmaceuticals, Inc., and early-stage candidates in preclinical development. The Business’s pipeline also includes 2ME2 (2-methoxyestradial). The Business’s primary research and development focuses on oncology therapeutics..